ADMA Biologics Appoints Plasma Industry Leader Lawrence Guiheen to Board of Directors

ADMA Biologics Appoints Plasma Industry Leader Lawrence Guiheen to Board of Directors

ADMA Biologics, Inc.

[email protected]

ADMA Biologics, Inc. (ADMA), a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today announced it has appointed Lawrence Guiheen to its Board of Directors. With the appointment of Mr. Guiheen, the Board of Directors will consist of seven members.

“We are very pleased to welcome Larry as a member of our Board of Directors, stated Steven Elms, Chairman of the Board of ADMA. “We look forward to utilizing his vast experience and relationships in the plasma and pharmaceutical industries as we continue to advance our product candidate’s development and expand our FDA-approved plasma operations.”

“Having previously served as President of BioPharmaceuticals for Baxter BioScience and the Chairman of the Global Board of Directors of the Plasma Protein Therapeutics Association, I am very pleased to join ADMA’s Board of Directors and look forward to sharing my experience and contributing to the Company’s future success,” commented Mr. Guiheen.

Mr. Guiheen is currently the principal of Guiheen and Associates LLC, a consulting group that specializes in biopharmaceuticals commercialization. Previous to this, he was President of BioPharmaceuticals for Baxter BioScience, where he managed sales and marketing of plasma and recombinant biotherapeutics in North America. Mr. Guiheen had been a senior member of the Baxter BioScience management team for over 10 years, setting the global strategy for the biopharmaceutical business. He was past Chairman of the Global Board of Directors of the Plasma Protein Therapeutics Association and past member of the Board of Directors of California Healthcare Institute. Mr. Guiheen holds a Bachelor of Science degree in business administration from Rutgers University.

ADMA is a late-stage biotechnology company which focuses its efforts on the development and commercialization of human plasma and plasma-derived therapeutics. ADMA’s mission is to develop and commercialize plasma-derived, human immune globulins targeted at niche patient populations with unmet medical needs. In addition, ADMA operates ADMA BioCenters, a wholly-owned subsidiary and FDA-licensed source plasma collection facility located in Norcross, Georgia.

This press release contains “forward looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely,” “should,” “could,” “would,” “may” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations, potential investigational new product applications, biologics license applications, and commercialization efforts of the Company's product candidate(s). Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks listed under the heading “Risk Factors” in Amendment No. 3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2012 and Amendment No. 3 to our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 3, 2012. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent to the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward looking statements or to announce revisions to any of the forward-looking statements.

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.